Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project
Open Access
- 31 December 2018
- journal article
- research article
- Published by BMJ in Lupus Science & Medicine®
- Vol. 6 (1), e000342
- https://doi.org/10.1136/lupus-2019-000342
Abstract
Objective Lupus is a complex, heterogeneous autoimmune disease that has yet to see significant progress towards more timely diagnosis, improved treatment options for short-term and long-term outcomes, and appropriate access to care. The Addressing Lupus Pillars for Health Advancement (ALPHA) project is the first step in establishing global consensus and developing concrete strategies to address the challenges limiting progress. Methods A Global Advisory Committee of 13 individuals guided the project and began barrier identification. Seventeen expert interviews were conducted to further characterise key barriers. Transcripts were analysed using Nvivo and a codebook was created containing a list of thematic 'nodes' (topics) and their descriptions. Findings were used to develop a final survey instrument that was fielded to a diverse, international stakeholder audience to achieve broad consensus. Results Expert interviews identified lupus heterogeneity as the primary barrier hindering advancement. Subsequent barriers were categorised into three areas: (1) Drug development. (2) Clinical care. (3) Access and value. The global survey received 127 completed responses from experts across 20 countries. Respondents identified barriers as high priority including the lack of biomarkers for clinical and drug development use, flawed clinical trial design, lack of access to clinicians familiar with lupus, and obstacles to effective management of lupus due to social determinants of care. Respondents also identified 30 autoimmune conditions that may be lupus-related based on overlapping features, shared autoantibodies and pathophysiology. Conclusions ALPHA is a comprehensive initiative to identify and prioritise the continuum of challenges facing people with lupus by engaging a global audience of lupus experts. It also explored views on lupus as a spectrum of related diseases. Conclusions from this effort provide a framework to generate actionable approaches to the identified high-priority barriers.Keywords
Funding Information
- GlaxoSmithKline
- EMD Serono
This publication has 30 references indexed in Scilit:
- Epidemiology of lupusCurrent Opinion in Rheumatology, 2015
- Patients with overlap autoimmune disease differ from those with ‘pure’ diseaseLupus Science & Medicine®, 2015
- Is SLE many single-organ diseases or an overlapping spectrum?Nature Reviews Rheumatology, 2015
- Exploring physician specialist response rates to web-based surveysBMC Medical Research Methodology, 2015
- Treat-to-target in systemic lupus erythematosus: recommendations from an international task forceAnnals Of The Rheumatic Diseases, 2014
- The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002–2004: The Georgia Lupus RegistryArthritis & Rheumatology, 2013
- Biomarkers in systemic lupus erythematosus: challenges and prospects for the futureTherapeutic Advances in Musculoskeletal Disease, 2013
- Disparities in lupus care and outcomesCurrent Opinion in Rheumatology, 2009
- Medicaid and access to care among persons with systemic lupus erythematosusArthritis Care & Research, 2007
- Autoantibodies and overlap syndromes in autoimmune rheumatic diseaseJournal of Clinical Pathology, 2001